Unwinding the complexities of helicases as compelling drug targets in oncology

Helicases are a promising and potentially significant target in the oncology clinical space but have previously been neglected due to challenges with high attrition rates and considerable sensitivity to false positives. In this poster, we describe and exemplify some of our experiences, learnings and best practices when prosecuting these compelling, but challenging, targets. We demonstrate our approach by characterising three commercially available WRN inhibitors from two distinct chemical series using a selection of biochemical and biophysical assays.

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.